Unknown

Dataset Information

Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells.


ABSTRACT: While CD19-directed chimeric antigen receptor (CAR) T cells can induce remission in patients with B cell acute lymphoblastic leukemia (ALL), a large subset relapse with CD19- disease. Like CD19, CD22 is broadly expressed by B-lineage cells and thus serves as an alternative immunotherapy target in ALL. Here we present the composite outcomes of two pilot clinical trials ( NCT02588456 and NCT02650414 ) of T cells bearing a 4-1BB-based, CD22-targeting CAR in patients with relapsed or refractory ALL. The primary end point of these studies was to assess safety, and the secondary end point was antileukemic efficacy. We observed unexpectedly low response rates, prompting us to perform detailed interrogation of the responsible CAR biology. We found that shortening of the amino acid linke

SUBMITTER: Singh N 

PROVIDER: S-EPMC8451032 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature